Evidence map›Paper›PMID 26659948›Full record

ArticleCirculation2016

Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies.

Lisandro D Colantonio, Vera Bittner, Kristi Reynolds, Emily B Levitan, Robert S Rosenson, Maciej Banach, Shia T Kent, Stephen F Derose, Hui Zhou, Monika M Safford and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Lisandro D ColantonioFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Vera BittnerFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Kristi ReynoldsFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Emily B LevitanFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Robert S RosensonFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Maciej BanachFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Shia T KentFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Stephen F DeroseFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Hui ZhouFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Monika M SaffordFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.).
Paul MuntnerFrom Department of Epidemiology (L.D.C., E.B.L., S.T.K., P.M.), Department of Medicine, Division of Cardiovascular Disease (V.B.), and Department of Medicine, Division of Preventive Medicine (M.M.S.), University of Alabama at Birmingham; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., S.F.D., Z.H.); Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); and Department of Hypertension, Medical University of Lodz, Poland (M.B.). pmuntner@uab.edu.
Icahn School of Medicine at Mount Sinai · USKaiser Permanente · USMedical University of Lodz · PL

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
REGARDS - MI StudyR01HL080477 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVITAN, EMILY B, SAFFORD, MONIKA M · 2006 to 2020
$11.6M
Building Capacity for Cardiometabolic Outcomes ResearchK24HL111154 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAFFORD, MONIKA M · 2012 to 2015
$556k
NHLBI NIH HHS K24 HL111154NHLBI NIH HHS K24-HL111154NHLBI NIH HHS R01 HL080477NHLBI NIH HHS R01-HL080477NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

backgroundThe use of statins increased among US adults with high coronary heart disease (CHD) risk after publication of the 2001 cholesterol treatment guidelines. METHODS AND

resultsWe analyzed the association between lipids and CHD among 9578 REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants and 346,595 Kaiser Permanente Southern California (KPSC) members with baseline lipid measurements in 2003 to 2007. We performed the same analyses among 14,590 Atherosclerosis Risk In Communities (ARIC) study participants with lipid measurements in 1987 to 1989. Analyses were restricted to blacks and whites 45 to 64 years of age without CHD who were not taking statins at baseline. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured at baseline. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated. The prevalence of diabetes mellitus, history of stroke, and antihypertensive medication use increased at higher low-density lipoprotein cholesterol in ARIC but not in REGARDS or KPSC. Over 8.9 years of follow-up, 225 CHD events occurred in REGARDS, 6547 events in KPSC, and 583 events in ARIC. After multivariable adjustment, less favorable lipid levels were associated with higher hazard ratios for CHD in ARIC. These associations were attenuated in REGARDS and KPSC. For example, the hazard ratio associated with the highest versus lowest quartile of low-density lipoprotein cholesterol (≥ 146 versus ≤ 102 mg/dL) was 1.89 (95% confidence interval, 1.42-2.51) in ARIC, 1.25 (95% confidence interval, 0.81-1.92) in REGARDS, and 1.49 (95% confidence interval, 1.38-1.61) in KPSC.

conclusionThe association between lipids and CHD in contemporary studies may be attenuated by the preferential use of statins by high-risk individuals.

Indexed as

Observational Studies as TopicCholesterolCholesterol, HDLCholesterol, LDLCoronary Artery DiseaseFemaleHumansLipoproteinsLipoproteins, HDLMaleMiddle AgedRisk FactorsSoutheastern United StatesTriglyceridesCholesterolCholesterol, HDLCholesterol, LDLLipoproteinsLipoproteins, HDLTriglyceridescoronary diseaseepidemiologyfollow-up studieslipids

Identifiers

PMID26659948
PMCPMC4718875
OpenAlexW2274399838

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.